Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News PolyPid Ltd. PYPD

PolyPid Ltd is a clinical stage specialty pharmaceutical company engaged in research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the Company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, BonyPid-1000, BonyPid-500, PLEX, and D-PLEX are trademarks of the Company. The Company is subject to extensive regulation by the FDA, under the Federal Food, Drug, and Cosmetic Act, as well as by other federal, state, and local regulatory agencies.


Recent & Breaking News (NDAQ:PYPD)

PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery

GlobeNewswire 2 days ago

PolyPid Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery

GlobeNewswire 11 days ago

PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the European Society for Coloproctology Scientific Conference

GlobeNewswire September 12, 2022

PolyPid Announces Top-line Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery

GlobeNewswire September 2, 2022

PolyPid Announces Presentation at the 2022 Military Health System Research Symposium

GlobeNewswire August 30, 2022

PolyPid Provides Corporate Update and Reports Second Quarter 2022 Financial Results

GlobeNewswire August 10, 2022

PolyPid Announces Exclusive Licensing Agreement with ADVANZ PHARMA for the Commercialization of D-PLEX₁₀₀ in Europe

GlobeNewswire August 3, 2022

PolyPid to Report Second Quarter 2022 Financial Results and Operational Highlights on August 10, 2022

GlobeNewswire July 27, 2022

PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the Midwest Surgical Association 2022 Annual Meeting

GlobeNewswire July 25, 2022

PolyPid Announces Dikla Czaczkes Akselbrad Assumes Role of CEO

GlobeNewswire July 5, 2022

PolyPid Hosting Key Opinion Leader Webinar on Managing the Cost of Surgical Site Infections

GlobeNewswire June 15, 2022

PolyPid Announces Presentation of D-PLEX₁₀₀ Phase 2 Clinical Data at ASM Microbe 2022

GlobeNewswire June 6, 2022

PolyPid to Present at the JMP Securities 2022 Life Sciences Conference

GlobeNewswire June 2, 2022

PolyPid Announces Publication of Animal Model Studies in 2022 ASCO Annual Meeting Abstract Demonstrating that Locally Administered OncoPLEX Potentially Decreases the Likelihood of Tumor Recurrence with Reduced Side Effects

GlobeNewswire June 1, 2022

PolyPid Announces Completion of Enrollment in Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for Prevention of Surgical Site Infections in Abdominal Surgery

GlobeNewswire May 31, 2022

PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis

GlobeNewswire May 23, 2022

PolyPid Provides Corporate Update and Reports First Quarter 2022 Financial Results

GlobeNewswire May 11, 2022

PolyPid to Report First Quarter 2022 Financial Results and Operational Highlights on May 11, 2022

GlobeNewswire April 27, 2022

PolyPid Announces Presentation at the 13th European and Global CLINAM Summit for Nanomedicine

GlobeNewswire April 25, 2022

PolyPid Announces Presentation of Clinical Data at Surgical Infection Society 2022 Annual Meeting

GlobeNewswire April 12, 2022